Nipun Chhabra, MD
Nipun Chhabra, MD is a board certified otolaryngologist with expertise in Rhinology and Endoscopic Skull Base Surgery. He is an Assistant Professor for Case Western Reserve University School of Medicine and is employed at University Hospitals of Cleveland and the Louis Stokes VA Medical Center. Dr. Chhabra completed his medical degree at George Washington University, residency at UH Case Medical Center, and a rhinology fellowship at the Massachusetts Eye and Ear Infirmary.
SINUVA® Sinus Implant is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps,
in patients ≥ 18 years of age who have had ethmoid sinus surgery.
IMPORTANT SAFETY INFORMATION
Patients with a known hypersensitivity to the mometasone furoate drug or any of the ingredients in SINUVA, should not use SINUVA. Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids. If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.
SINUVA is made from bioabsorbable polymers designed to soften over time. As the implant softens and polyps decrease, the implant may be expelled out of the nose on its own or with actions such as sneezing or forceful nose blowing. The implant can be removed 90 days after placement or earlier at the physician’s discretion. Repeat administration of SINUVA has not been studied.
As with other endoscopic sinus procedures, there are risks associated with the insertion or removal of SINUVA. SINUVA should be inserted by physicians trained in otolaryngology.
The nasal mucosa adjacent to the SINUVA Sinus Implant should be monitored for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid the use of SINUVA in patients with nasal ulcers or trauma.
The most common adverse reactions observed (in more than 1% of subjects and more commonly in the treatment group) in clinical studies were bronchitis, nasopharyngitis, otitis media, headache, presyncope, asthma, and epistaxis.
Patients experiencing excessive nasal bleeding, worsening of existing tuberculosis, fungal, bacterial, viral or parasitic infection, ocular herpes, or symptoms suggesting that the implant has moved, such as irritation or a choking sensation in the back of the throat, should immediately contact a healthcare professional.
Close monitoring is recommended if patients have a change of vision or a history of increased intraocular pressure, glaucoma and/or cataracts.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch (www.fda.gov/medwatch) or call
1-800-FDA-1088. You may also report side effects to Intersect ENT at 1-866-531-6004.
RX Only. For important risk and use information about SINUVA, please see Full Prescribing Information at www.sinuva.com/pi.
Intersect ENT, PROPEL and SINUVA are registered trademarks of Intersect ENT, Inc. in the United States and other countries. ©2019 Intersect ENT, Inc. All rights reserved.